Compounds > irofulven
Page last updated: 2024-09-04

irofulven and Carcinoma, Anaplastic

irofulven has been researched along with Carcinoma, Anaplastic in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Comisso, M; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ1
Cvitkovic, E; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ1
Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P1

Other Studies

3 other study(ies) available for irofulven and Carcinoma, Anaplastic

ArticleYear
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carcinoma; Cell Line, Tumor; Cisplatin; Culture Media; Dioxoles; Drug Resistance, Neoplasm; Epithelial Cells; Glutamate-Cysteine Ligase; Glutathione Transferase; Humans; Isoquinolines; Models, Chemical; Plant Extracts; Polycyclic Sesquiterpenes; rho GTP-Binding Proteins; Sesquiterpenes; Tetrahydroisoquinolines; Time Factors; Trabectedin; Tumor Suppressor Protein p53

2003
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
    International journal of oncology, 2003, Volume: 23, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Models, Chemical; Ovarian Neoplasms; Sesquiterpenes; Tetrazolium Salts; Thiazoles

2003
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Altretamine; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; DNA Damage; DNA, Neoplasm; Drug Synergism; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Random Allocation; Sesquiterpenes; Transcription, Genetic; Xenograft Model Antitumor Assays

2008